The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.
Peg-Intron for Prevention of Disease Progression in Chronic Hepatitis C Patients with Cirrhosis who failed with a Interferon plus Ribavirin Therapy
– Chronic Hepatitis C- Cirrhosis
Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Eligibility & Criteria
Ages Eligible for Study: 18 Years – 65 Years, Genders Eligible for Study: Both Criteria Inclusion Criteria:Age at entry 18-65 years; non-responders to previous treatment (minimum of 3 months) with an a interferon plus ribavirin; liver biopsy demonstrating cirrhosis Exclusion Criteria:Any other cause for liver disease other than chronic hepatitis C; history or presence of complications of cirrhosis; alcohol or illicit drug abuse or treatment with methadone within the past 2 years; diseases or conditions that could interfere with participation in the study
Contact Details Westmead Hospital, Sydney, Australia  Alfred Hosptial, Melbourne, Australia
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.